King K L, Winer J, Phillips D M, Quach J, Williams P M, Mather J P
Genentech, Inc., South San Francisco, CA 94080, USA.
Endocrine. 1998 Aug;9(1):45-55. doi: 10.1385/endo:9:1:45.
In these studies, we show that endothelin (ET), leukemia inhibitory factor (LIF), phenylephrine (PE), and prostaglandin F2alpha (PGF2alpha), which are all hypertrophic for neonatal rat cardiac myocytes in culture, induce distinct morphological, physiological, and genetic changes after a 48-h treatment. Transmission electron microscopy revealed differences in myofibril organization, with ET-treated cells containing the most mature-looking myofibrils and PGF2alpha- and LIF-treated cells the least. ET- and PE-treated cultures contained the same number of beating cells as control, but LIF and PGF2alpha treatment increased the number of beating cells 180%. Treatment with LIF, PE, and PGF2alpha increased the beat rate to 3.3 times that of control. After exposure to the beta-adrenergic agonist isoproterenol, the beat rate increased 50% for PGF2alpha' 54% for PE, 84% for LIF, and 125% for control. ET treatment did not increase the beat rate, nor did these cells respond to isoproterenol. ET, LIF, and PE increased the production of atrial natriuretic peptide (ANP) by three-fold and PGF2alpha by 18-fold over nontreated cells. Brain natriuretic peptide (BNP) was increased fourfold by ET and PE, 16-fold by LIF, and 29-fold by PGF2alpha. Interestingly, on a pmol/L basis, only LIF induced more BNP than ANP. Treatment with all agents led to a similar pattern of gene induction: increased expression of the embryonic genes for ANP and skeletal alpha-actin, and less than a twofold change in the constitutively expressed gene myosin light chain-2, with the exception that LIF did not induce skeletal alpha-actin. Each agent, however, induced ANP mRNA with a different time-course. We conclude that at least four distinct cardiac myocyte hypertrophy response programs can be induced in vitro. Further studies are necessary to determine whether these correlate to the different types of cardiac hypertrophy seen in vivo.
在这些研究中,我们发现内皮素(ET)、白血病抑制因子(LIF)、去氧肾上腺素(PE)和前列腺素F2α(PGF2α),在体外培养时均可使新生大鼠心肌细胞肥大,经过48小时的处理后,它们会诱导明显的形态、生理和基因变化。透射电子显微镜显示肌原纤维组织存在差异,ET处理的细胞含有看起来最成熟的肌原纤维,而PGF2α和LIF处理的细胞则最少。ET和PE处理的培养物中跳动细胞的数量与对照相同,但LIF和PGF2α处理使跳动细胞的数量增加了180%。用LIF、PE和PGF2α处理可使搏动率提高到对照的3.3倍。在暴露于β-肾上腺素能激动剂异丙肾上腺素后,PGF2α处理的搏动率增加了50%,PE处理的增加了54%,LIF处理的增加了84%,对照处理的增加了125%。ET处理并未增加搏动率,这些细胞对异丙肾上腺素也无反应。与未处理的细胞相比,ET、LIF和PE使心钠素(ANP)的产生增加了三倍,PGF2α使心钠素增加了18倍。脑钠素(BNP)经ET和PE处理后增加了四倍,经LIF处理后增加了16倍,经PGF2α处理后增加了29倍。有趣的是,以皮摩尔/升为单位,只有LIF诱导产生的BNP比ANP多。所有药物处理均导致类似的基因诱导模式:ANP和骨骼肌α-肌动蛋白的胚胎基因表达增加,组成性表达的肌球蛋白轻链-2基因的变化不到两倍,不同的是LIF未诱导骨骼肌α-肌动蛋白。然而,每种药物诱导ANP mRNA的时间进程不同。我们得出结论,体外至少可诱导出四种不同的心肌细胞肥大反应程序。需要进一步研究以确定这些程序是否与体内所见的不同类型心肌肥大相关。